Patent ID: 11896657
Assignee: GEOVAX, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 8:
9. A recombinant modified vaccinia ankara (MVA) vector comprising:
i) a first nucleic acid sequence encoding a Marburg virus glycoprotein comprising nucleic acids 1631-3676 of SEQ ID NO:15, or a nucleic acid sequence at least 95% identical thereto, and
ii) a second nucleic acid sequence encoding a Marburg virus VP40 matrix protein comprising nucleic acids 1581-2492 of SEQ ID NO:14, or a nucleic acid sequence at least 95% identical thereto;
wherein both the first nucleic acid sequence and the second nucleic acid sequence are under the control of one or more promoters compatible with poxvirus expression systems;
wherein the first nucleic acid is located between MVA genes I8R and G1L;
wherein the second nucleic acid sequence is located between MVA genes A50R and B1R in a restructured and modified deletion site III; and
wherein the Marburg virus glycoprotein and the Marburg virus VP40 matrix protein are capable of assembling into virus-like particles (VLPs) when expressed in a host cell.